Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Washington University School of Medicine
Genentech, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cedars-Sinai Medical Center
Celldex Therapeutics
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
Nantes University Hospital
Pfizer
National Institutes of Health Clinical Center (CC)
University of Dundee
Celgene
National Institutes of Health Clinical Center (CC)
N.N. Petrov National Medical Research Center of Oncology
Stanford University
Comprehensive Cancer Centers of Nevada
Ohio State University Comprehensive Cancer Center
Santa Maria Biotherapeutics
Virginia Commonwealth University
The Cleveland Clinic
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Indiana University
University of Chicago
University of Chicago
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Hoag Memorial Hospital Presbyterian
Hoag Memorial Hospital Presbyterian
Fred Hutchinson Cancer Center
ZymoGenetics